Clinical Trial Update: SCH-58235 (Ezetimibe) to Treat Homozygous Sitosterolemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial tested ezetimibe (SCH-58235) for homozygous sitosterolemia and has completed; the study was sponsored by the NHLBI.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sitosterolemia

Drugs mentioned

• EZETIMIBE (EZETIMIBE)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Lipoidosis | Phase 2 | Status: COMPLETED